Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the USH2A gene.
Features include: Bone spicule pigmentation of the retina, Visual field defect, Visual impairment, and Rod-cone dystrophy and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 2 | Visual impairment, Attenuation of retinal blood vessels |
USH2A function has not been fully characterized.
Retinitis pigmentosa 39 is associated with mutations in the USH2A gene on chromosome 1.
Genetic testing for USH2A is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 39 has been reported in the published literature.
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
151 publications have been identified in PubMed for retinitis pigmentosa 39. Kisho has analyzed 90 by research type. Research spans Epidemiology / Natural History (32%), Basic Science / Preclinical (23%), and Diagnostic / Biomarker (11%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 29 |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 7:17 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1 |
Bone spicule pigmentation of the retina |
Laboratory research | 21 | 23% |
Testing and diagnosis research | 10 | 11% |
Research summaries | 9 | 10% |
Clinical study results | 8 | 9% |
Patient case studies | 6 | 7% |
New treatment approaches | 6 | 7% |
Other research | 1 | 1% |
Salim Al-Hamdani SZ (2026). [PMID: 41961253](https://pubmed.ncbi.nlm.nih.gov/41961253/). *Graefes Arch Clin Exp Ophthalmol*. [Clinical Trial Publication]
Marsh K (2026). [PMID: 41697461](https://pubmed.ncbi.nlm.nih.gov/41697461/). *Pharmacoecon Open*. [Epidemiology / Natural History]
Dhanji SR (2026). [PMID: 41782259](https://pubmed.ncbi.nlm.nih.gov/41782259/). *Ophthalmic Genet*. [Case Report / Case Series]
Asadollahzadeh E (2026). [PMID: 41767075](https://pubmed.ncbi.nlm.nih.gov/41767075/). *Clin Case Rep*. [Case Report / Case Series]
Zaydon Y (2026). [PMID: 42106178](https://pubmed.ncbi.nlm.nih.gov/42106178/). *Handb Clin Neurol*. [Review / Meta-Analysis]
Kim J (2026). [PMID: 42001345](https://pubmed.ncbi.nlm.nih.gov/42001345/). *Hum Cell*. [Basic Science / Preclinical]
Liang Y (2026). [PMID: 41864154](https://pubmed.ncbi.nlm.nih.gov/41864154/). *Stem Cell Res*. [Basic Science / Preclinical]
Abu Serhan H (2026). [PMID: 41721385](https://pubmed.ncbi.nlm.nih.gov/41721385/). *Int J Retina Vitreous*. [Review / Meta-Analysis]
Schäfer D (2026). [PMID: 41423877](https://pubmed.ncbi.nlm.nih.gov/41423877/). *Angew Chem Int Ed Engl*. [Basic Science / Preclinical]
Al-Moujahed A (2026). [PMID: 41891913](https://pubmed.ncbi.nlm.nih.gov/41891913/). *Ophthalmic Surg Lasers Imaging Retina*. [Epidemiology / Natural History]